The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

David L. Schwartz, Garth Powis, Arun Thitai-Kumar, Yi He, James Bankson, Ryan Williams, Robert Lemos, Junghwan Oh, Andrei Volgin, Suren Soghomonyan, Ryuichi Nishii, Mian Alauddin, Uday Mukhopadhay, Zhenghong Peng, William Bornmann, Juri Gelovani

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Hypoxia inducible factor-1 (HIF-1) promotes tumor cell adaptation to microenvironmental stress. HIF-1 is up-regulated in irradiated tumors and serves as a promising target for radiosensitization. We initially confirmed that the orally bioavailable HIF-1 inhibitor PX-478 reduces HIF-1 protein levels and signaling in vitro in a dose-dependent manner and provides direct radiosensitization of hypoxic cancer cells in clonogenic survival assays using C6 glioma, HN5 and UMSCCa10 squamous cells, and Panc-1 pancreatic adenocarcinoma cell lines. However, PX-478 yields striking in vivo tumor sensitization to single-dose irradiation, which cannot be explained by incremental improvement in direct tumor cell killing. We show that PX-478 prevents postradiation HIF-1 signaling and abrogates downstream stromal adaptation in C6 and HN5 reporter xenografts as measured by serial ultrasound, vascular magnetic resonance imaging, and hypoxia response element-specific micro-positron emission tomography imaging. The primacy of indirect PX-478 in vivo effects was corroborated by our findings that (a) either concurrent or early postradiation sequencing of PX-478 provides roughly equivalent sensitization and (b) constitutive vascular endothelial growth factor expression maintains refractory tumor vessel function and progression following combined radiation and PX-478. These results confirm that disruption of postradiation adaptive HIF-1 signaling by PX-478 imparts increased therapeutic efficacy through blockade of HIF-1-dependent reconstitution of tumor stromal function. Successful translation of targeted HIF-1 radiosensitization to the clinical setting will require specific consideration of tumor microenvironmental effects and mechanisms.

Original languageEnglish (US)
Pages (from-to)947-958
Number of pages12
JournalMolecular Cancer Therapeutics
Volume8
Issue number4
DOIs
StatePublished - Apr 1 2009

Fingerprint

Hypoxia-Inducible Factor 1
Neoplasms
2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide
Response Elements
Heterografts
Glioma
Positron-Emission Tomography
Vascular Endothelial Growth Factor A
Blood Vessels
Adenocarcinoma
Epithelial Cells
Magnetic Resonance Imaging
Radiation
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. / Schwartz, David L.; Powis, Garth; Thitai-Kumar, Arun; He, Yi; Bankson, James; Williams, Ryan; Lemos, Robert; Oh, Junghwan; Volgin, Andrei; Soghomonyan, Suren; Nishii, Ryuichi; Alauddin, Mian; Mukhopadhay, Uday; Peng, Zhenghong; Bornmann, William; Gelovani, Juri.

In: Molecular Cancer Therapeutics, Vol. 8, No. 4, 01.04.2009, p. 947-958.

Research output: Contribution to journalArticle

Schwartz, DL, Powis, G, Thitai-Kumar, A, He, Y, Bankson, J, Williams, R, Lemos, R, Oh, J, Volgin, A, Soghomonyan, S, Nishii, R, Alauddin, M, Mukhopadhay, U, Peng, Z, Bornmann, W & Gelovani, J 2009, 'The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects', Molecular Cancer Therapeutics, vol. 8, no. 4, pp. 947-958. https://doi.org/10.1158/1535-7163.MCT-08-0981
Schwartz, David L. ; Powis, Garth ; Thitai-Kumar, Arun ; He, Yi ; Bankson, James ; Williams, Ryan ; Lemos, Robert ; Oh, Junghwan ; Volgin, Andrei ; Soghomonyan, Suren ; Nishii, Ryuichi ; Alauddin, Mian ; Mukhopadhay, Uday ; Peng, Zhenghong ; Bornmann, William ; Gelovani, Juri. / The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 4. pp. 947-958.
@article{34199c46b9fe4220bdd65931a62e676f,
title = "The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects",
abstract = "Hypoxia inducible factor-1 (HIF-1) promotes tumor cell adaptation to microenvironmental stress. HIF-1 is up-regulated in irradiated tumors and serves as a promising target for radiosensitization. We initially confirmed that the orally bioavailable HIF-1 inhibitor PX-478 reduces HIF-1 protein levels and signaling in vitro in a dose-dependent manner and provides direct radiosensitization of hypoxic cancer cells in clonogenic survival assays using C6 glioma, HN5 and UMSCCa10 squamous cells, and Panc-1 pancreatic adenocarcinoma cell lines. However, PX-478 yields striking in vivo tumor sensitization to single-dose irradiation, which cannot be explained by incremental improvement in direct tumor cell killing. We show that PX-478 prevents postradiation HIF-1 signaling and abrogates downstream stromal adaptation in C6 and HN5 reporter xenografts as measured by serial ultrasound, vascular magnetic resonance imaging, and hypoxia response element-specific micro-positron emission tomography imaging. The primacy of indirect PX-478 in vivo effects was corroborated by our findings that (a) either concurrent or early postradiation sequencing of PX-478 provides roughly equivalent sensitization and (b) constitutive vascular endothelial growth factor expression maintains refractory tumor vessel function and progression following combined radiation and PX-478. These results confirm that disruption of postradiation adaptive HIF-1 signaling by PX-478 imparts increased therapeutic efficacy through blockade of HIF-1-dependent reconstitution of tumor stromal function. Successful translation of targeted HIF-1 radiosensitization to the clinical setting will require specific consideration of tumor microenvironmental effects and mechanisms.",
author = "Schwartz, {David L.} and Garth Powis and Arun Thitai-Kumar and Yi He and James Bankson and Ryan Williams and Robert Lemos and Junghwan Oh and Andrei Volgin and Suren Soghomonyan and Ryuichi Nishii and Mian Alauddin and Uday Mukhopadhay and Zhenghong Peng and William Bornmann and Juri Gelovani",
year = "2009",
month = "4",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0981",
language = "English (US)",
volume = "8",
pages = "947--958",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects

AU - Schwartz, David L.

AU - Powis, Garth

AU - Thitai-Kumar, Arun

AU - He, Yi

AU - Bankson, James

AU - Williams, Ryan

AU - Lemos, Robert

AU - Oh, Junghwan

AU - Volgin, Andrei

AU - Soghomonyan, Suren

AU - Nishii, Ryuichi

AU - Alauddin, Mian

AU - Mukhopadhay, Uday

AU - Peng, Zhenghong

AU - Bornmann, William

AU - Gelovani, Juri

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Hypoxia inducible factor-1 (HIF-1) promotes tumor cell adaptation to microenvironmental stress. HIF-1 is up-regulated in irradiated tumors and serves as a promising target for radiosensitization. We initially confirmed that the orally bioavailable HIF-1 inhibitor PX-478 reduces HIF-1 protein levels and signaling in vitro in a dose-dependent manner and provides direct radiosensitization of hypoxic cancer cells in clonogenic survival assays using C6 glioma, HN5 and UMSCCa10 squamous cells, and Panc-1 pancreatic adenocarcinoma cell lines. However, PX-478 yields striking in vivo tumor sensitization to single-dose irradiation, which cannot be explained by incremental improvement in direct tumor cell killing. We show that PX-478 prevents postradiation HIF-1 signaling and abrogates downstream stromal adaptation in C6 and HN5 reporter xenografts as measured by serial ultrasound, vascular magnetic resonance imaging, and hypoxia response element-specific micro-positron emission tomography imaging. The primacy of indirect PX-478 in vivo effects was corroborated by our findings that (a) either concurrent or early postradiation sequencing of PX-478 provides roughly equivalent sensitization and (b) constitutive vascular endothelial growth factor expression maintains refractory tumor vessel function and progression following combined radiation and PX-478. These results confirm that disruption of postradiation adaptive HIF-1 signaling by PX-478 imparts increased therapeutic efficacy through blockade of HIF-1-dependent reconstitution of tumor stromal function. Successful translation of targeted HIF-1 radiosensitization to the clinical setting will require specific consideration of tumor microenvironmental effects and mechanisms.

AB - Hypoxia inducible factor-1 (HIF-1) promotes tumor cell adaptation to microenvironmental stress. HIF-1 is up-regulated in irradiated tumors and serves as a promising target for radiosensitization. We initially confirmed that the orally bioavailable HIF-1 inhibitor PX-478 reduces HIF-1 protein levels and signaling in vitro in a dose-dependent manner and provides direct radiosensitization of hypoxic cancer cells in clonogenic survival assays using C6 glioma, HN5 and UMSCCa10 squamous cells, and Panc-1 pancreatic adenocarcinoma cell lines. However, PX-478 yields striking in vivo tumor sensitization to single-dose irradiation, which cannot be explained by incremental improvement in direct tumor cell killing. We show that PX-478 prevents postradiation HIF-1 signaling and abrogates downstream stromal adaptation in C6 and HN5 reporter xenografts as measured by serial ultrasound, vascular magnetic resonance imaging, and hypoxia response element-specific micro-positron emission tomography imaging. The primacy of indirect PX-478 in vivo effects was corroborated by our findings that (a) either concurrent or early postradiation sequencing of PX-478 provides roughly equivalent sensitization and (b) constitutive vascular endothelial growth factor expression maintains refractory tumor vessel function and progression following combined radiation and PX-478. These results confirm that disruption of postradiation adaptive HIF-1 signaling by PX-478 imparts increased therapeutic efficacy through blockade of HIF-1-dependent reconstitution of tumor stromal function. Successful translation of targeted HIF-1 radiosensitization to the clinical setting will require specific consideration of tumor microenvironmental effects and mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=66449118481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449118481&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0981

DO - 10.1158/1535-7163.MCT-08-0981

M3 - Article

C2 - 19372568

AN - SCOPUS:66449118481

VL - 8

SP - 947

EP - 958

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -